Close Menu

NEW YORK (GenomeWeb) – CareDx and French medical technology firm Cibiltech announced today that they are partnering to commercialize Predigraft, a data analysis tool that provides an early prediction of an individual's risk of allograft rejection and transplant loss.

Under the terms of the agreement, CareDx will hold the exclusive rights to commercialize Predigraft in the US and will also become a minority equity owner of Cibiltech. The companies have also agreed to collaborate to advance the development of artificial intelligence in transplant care.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Retraction Watch reports that a paper was pulled because it refers to a gene that doesn't exist in mice.

Researchers were able to generate fertilized northern white rhinoceros eggs, according to Mashable.

Former Orig3n employees raise concerns about its testing at Bloomberg Businessweek.

In PLOS this week: microRNA expression changes in hepatocellular carcinoma, real-time PCR-based approach for diagnosing schistosomiasis, and more.